Effect of Ketorolac and Remote Ischemic Preconditioning on Renal Ischemia-reperfusion Injury in Patients Undergoing Partial Nephrectomy

Not Applicable

Completed

• Conditions: Renal Cell Carcinoma
• Interventions: Drug: Ketorolac tromethamine and remote ischemic preconditioning

• Registration Number: NCT01836406
• Lead Sponsor: Yonsei University

Brief Summary

Partial nephrectomy is a widely accepted alternative to radical nephrectomy in patients with clinically localized, unilateral renal cell carcinoma and a normal contralateral kidney. Interruption of renal blood flow via pedicle clamping is often necessary during partial nephrectomy, especially for complex tumors with deep parenchymal invasion. Ischemia-reperfusion injury is a complex process involving several mechanisms including renal vasoconstriction, extensive tubular damage and glomerular injury. The investigators will examine the postoperative renal function of patients who received intraoperative ketorolac and remote ischemic preconditioning during partial nephrectomy.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2012-12
• Study First Submitted: 2013-04-16
• Study First Submitted QC: 2013-04-18
• Study First Posted: 2013-04-19
• Primary Completion: 2013-06
• Study Completion: 2013-06
• Status Verified: 2014-02
• Last Update Submitted: 2014-02-17
• Last Update Posted: 2014-02-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

• ASA l and ll
• age 20-65
• patients undergoing partial nephrectomy

Read More

Exclusion Criteria

• preoperative liver or renal dysfunction,
• coagulopathy,
• chronic alcoholism,
• hypersensitivity of NSAID,
• history of warfarin,
• history of gastric ulcer

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Keromin Group	Ketorolac tromethamine and remote ischemic preconditioning	-

Primary Outcome Measures

Name	Time	Method
serum creatinine	at baseline, 2 hr, 12hr, 24 hr, 48 hr, 72 hr after clamping release

Secondary Outcome Measures

Name	Time	Method
Creatinine clearance	at baseline, 2 hr, 12hr, 24 hr, 48 hr, 72 hr after clamping release
urinary NAG	at base line, 2 hr, 12 hr after clamping release
serum NGAL	at base line, 2 hr, 12 hr after clamping release

Trial Locations

Locations (1)

Severance hospital; 🇰🇷 Seoul, Korea, Republic of